However, with the advances of knowledge in the pathogenesis of neutropenia in GSD-1b, sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as empagliflozin, were found to lower 1,5-AG6P concentration in neutrophils by indirectly inhibiting renal reabsorption of 1,5-anhydroglucitol (3, 5–10). This evidence concerns the gene SLC5A2 and glycogen storage disease Ib.